Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers ...

Dr. Michael Traxlmayr detailed how engineered protein “building blocks” can give CAR T cells new abilities, from ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ ...

Researchers successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple ...

CAR T-cell therapy demand is rising, prompting institutions to expand access and reduce care barriers, exemplified by Vanderbilt-Ingram Cancer Center's outpatient center. Dr. Oluwole emphasizes ...

A new in vivo approach to chimeric antigen receptor T-cell (CAR-T) therapy could extend the technology’s use beyond cancer, as a treatment for autoimmune disease (Science 2025, DOI: 10.1126 ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan to add an early-phase autoimmune candidate to its pipeline.